Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jeanifer Gachev"'
Autor:
Petra Muus, Nicola Houghton, Lindsay Mitchell, Jeanifer Gachev, Kathryn Riley, Louise Arnold, Alexandra Pike, Morag Griffin, Tahla Munir, Peter Hillmen, Briony Forrest
Publikováno v:
British Journal of Haematology
Autor:
Morag Griffin, Rachael Jones, Louise Arnold, Jeanifer Gachev, Kathryn Riley, Petra Muus, Briony Forrest, Peter Hillmen, Talha Munir, Alexandra Pike, Ray Borrow, Richard Kelly
Publikováno v:
Blood. 136:5-6
Eculizumab, the monoclonal antibody targeting C5, is the only licensed treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) in the UK. Inherent to the mechanism of action, C5 inhibitors increase patient susceptibility to encapsulated microorganism
Autor:
Briony Forrest, Peter Hillmen, Kathryn Riley, Jeanifer Gachev, Petra Muus, Morag Griffin, Alexandra Pike, Talha Munir, Richard Kelly, Louise Arnold
Publikováno v:
Blood. 136:35-36
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hemolytic and thrombotic condition. Patients can experience severe anemia due to intravascular hemolysis, thrombotic events, renal impairment and pulmonary hypertension. Symptomatic patients are tre
Autor:
Rachael Jones, Talha Munir, Alexandra Pike, Petra Muus, Louise Arnold, Morag Griffin, Peter Hillmen, Jeanifer Gachev, Briony Forrest
Publikováno v:
Blood. 136:8-9
Background Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare acquired disorder characterised by intravascular hemolysis and thrombosis. Patients with symptomatic PNH are commenced on the complement inhibitor eculizumab (600mg weekly for 5 weeks the